Enhance Genetics Body Building
New posts
Install the app
How to install the app on iOS

Follow along with the video below to see how to install our site as a web app on your home screen.

Note: This feature may not be available in some browsers.


FDA receives Actavis' NDA resubmission for cariprazine

E

EGBOT

Guest
FDA receives Actavis' NDA resubmission for cariprazine

HTML: 
Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

Source: FDA receives Actavis' NDA resubmission for cariprazine
 

Create an account or login to comment

You must be a member in order to leave a comment

Create account

Create an account on our community. It's easy!

Register

Log in

Already have an account? Log in here.

Latest threads

Back
Top